- Home
- TTGT vs FHTX Comparison
TTGT vs FHTX Comparison
Compare TTGT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | FHTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.1M | 360.8M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TTGT | FHTX |
|---|---|---|
| Price | $5.50 | $5.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $11.25 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 317.1K | 193.4K |
| Earning Date | 11-10-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $446,514,000.00 | $24,518,000.00 |
| Revenue This Year | $74.33 | $40.91 |
| Revenue Next Year | $3.55 | $11.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.55 | N/A |
| 52 Week Low | $4.63 | $2.95 |
| 52 Week High | $19.29 | $6.95 |
Technical Indicators
Market Signals| Indicator | TTGT | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 54.56 |
| Support Level | $5.02 | $5.55 |
| Resistance Level | $5.59 | $6.29 |
| Average True Range (ATR) | 0.28 | 0.50 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 55.90 | 52.81 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.